Cysteine protease inhibitor stefin A in murine tumors during treatment by Ukrain and/or cyclophosphamide

International Journal of Immunotherapy

Volumn 19, Issue 2-4, 2003, Pages 151-157

  Korolenko, T A ^a   Falameyeva, O V ^a   Poteryaeva, O N ^b   Zhanaeva, S Y ^a   Levina, O A ^a   Nowicky, J W ^c  

^a INSTITUTE OF PHYSIOLOGY   (Russian Federation)

^b Institute of Biochemistry   (Russian Federation)

^c Ukrainian Anti Cancer Institute   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1,3 GLUCAN; CYCLOPHOSPHAMIDE; CYSTATIN C; CYSTEINE PROTEINASE INHIBITOR; STEFIN A; UKRAIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD LEVEL; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL NEOPLASM; LEWIS CARCINOMA; LIVER CELL CARCINOMA; LIVER LEVEL; LUNG ADENOCARCINOMA; LYMPHOSARCOMA; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; SPLEEN; TISSUE LEVEL;

EID: 6944250157     PISSN: 02559625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Kos J., Stabuc B., Schweiger A., et al. Cathepsins B, H, and L and their inhibitors Stefin A and cystatin C in sera of melanoma patients. Clinic. Cancer Res., 3, 1815, 1997.
2. Kos J., Lah T.T. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol. Rep., 5, 1349, 1998.
3. Kos J., Krasovec M., Cimerman N., Nielsen H.J., Christensen I.J., Brunner N. Cysteine proteinase inhibitors stefin A, stefin B, and cystatin C in sera from patients with colorectal cancer: relation to prognosis. Clin. Cancer Res., 6, 505, 2000.
4. Kos J., Werle B., Lah T., Brunner N. Cysteine proteinases and their inhibitors in extracellular fluids: Markers for diagnosis and prognosis in cancer. Int. J. Biol. Markers, 15, 84, 2000.
5. Lah T.T., Kokalj-Kunovar M., Kastelic L., et al. Cystatins and stefins in ascites fluid from ovarian carcinoma. Cancer Lett., 61, 243, 1992.
6. Lah T.T., Kokalj-Kunovar M., Strukelj B., et al Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. Int. J. Cancer, 50, 36, 1992.
7. Lah T.T, Kos J. Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol Chem., 379, 125, 1998.
8. Boike G., Lah T., Sloane B.F., et al. A possible role for cysteine proteinases and its inhibitors in motility of malignant melanoma and other tumour cells. Melanoma Res. 1, 333, 1991.
9. Calkins C.C., Sloane B.F. Mammalian cysteine protease inhibitors: Biochemical properties and possible roles in tumor progression. Biol. Chem. Hoppe Seyler, 376, 71, 1995.
10. Sloane B.F., Moin K., Lah T.T. Regulation of lysosomal endopeptidases in neoplasia. In: Pretlow T.G. and Pretlow T.P. (Eds. . "Biochemical and Molecular Aspects of Selected Cancers." Academic Press, San Diego, 1994, pp. 411-466.
11. Turk V., Bode W. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett., 285, 213, 1991.
12. Turk B., Turk V., Turk D. Structural and functional aspects of papain-like cysteine proteinases and their protein inhibitors. Biol. Chem., 378, 141, 1997.
13. Turk B., Turk D., Turk V. Lysosomal cysteine proteases. More than scavengers. Biochim. Biophys. Acta, 1477, 98, 2000.
14. Ebert E., Werle B., Julke B., et al. Expression of cysteine protease inhibitors stefin A, stefin B and cystatin C in human lung tumor tissue. Adv. Exp. Med. Biol., 421, 259, 1997.
15. Friedrich B., Jung K., Lein M., et al. Cathelosins B, H, L and cysteine protease inhibitors in malignant prostatic lines, primary cultured prostatic cells and prostatic tissue. Eur. J. Cancer, 35 138, 1999.
16. Heidtmann H.H., Salge U., Abrahamson M., et al. Cathepsin B and cysteine proteinase inhibitors in human lung cancer cell lines. Clin. Exp. Metastasis, 15, 368, 1997.
17. Kuopio T., Kankaanranta A., Jalava P., et al. Cysteine proteinase inhibitors stefin A in breast cancer. Cancer Res., 58 432, 1998.
18. Korolenko T.A., Poteryaeva O.N., Djanayeva S.J., et al. Cystatin C in LS lymphosarcoma and HA-1 hepatoma treated by Ukrain and cyclophosphamide and involvement of apoptosis. Drugs. Exptl. Clin. Res., 26, 65, 2000.
19. Poteryaeva O.N., Falameyeva O.V., Korolenko T.A., et al. Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice. Drugs Exptl. Clin. Res., 26, 137, 2000.
20. Russo A., Bazan V., Migliavacca M., et al. Prognostic significance of DNA ploidy, S-phase fraction, and tissue levels of aspartic, cysteine, and serine proteases in operable gastric carcinoma. Clin. Cancer Res , 6, 178, 2000.
21. Hibbetts K., Hines B., Williams D. An overview of proteinase inhibitors. J. Vet. Intern. Med., 13, 302, 1999.
22. Leto G., Tumminello F.M., Pizzolanti G., Montalto G., Soresi M., Gebbia N. Lysosomal cathepsin B and L and Stefin A blood levels in patients with hepatocellular carcinoma and/or liver cirrhosis: Potencial clinical implications. Oncology, 54, 79, 1997.
23. Reinheckel T., Deussing J., Roth V., Peters C. Towards specific functions of lysosomal cysteine peptidases: Phenotypes of mice deficient for cathepsin B or cathepsin L. Biol. Chem., 382, 735, 2001.
24. Sinha A.A., Quast B.J., Korkowski J.C., et al. The relationship of cathepsin B and stefin A mRNA localization identifies a potencially aggressive variant of human prostate cancer within a Gleason histologic score. Anticancer Res., 19, 2821, 1999.
25. Strojnik T., Zajc I., Bervar A., et al. Cathepsin B and its inhibitor stefin A in brain tumors. Pflugers Arch., 439, 122, 2000.
26. Kastelic L., Turk B., Kopitar-Jerala N., et al. Stefin B, the major low molecular weight inhibitor in ovarian carcinoma. Cancer Lett, 82, 81, 1994.
27. Strojan P., Budihna M., Smid L., et al. Prognostic significance of cysteine proteinases catepsins B and L and their endogenous inhibitors stefins A and B in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res., 6, 1052, 2000.
28. Budihna M., Strojan P., Smid L., et al Prognostic value of cathepsins B, H, L, D, and their endogenous inhibitors stefins A and B in head and neck carcinoma. Biol. Chem. Hoppe Seyler, 6, 385, 1996.
29. Vray B., Hartmann S., Hoebeke J. Immunomodulatory properties of cystatins. Cell. Mol. Life Sci. 59, 1503, 2002.